JP Morgan Chase
SAGE

JP Morgan Chase’s Sage Therapeutics SAGE Stock Holding History

JP Morgan Chase’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132,912
Closed -$1.21M – 7680
2025
Q2 		$1.21M Buy
132,912
+106,474
+403% +$783K ﹤0.01% 4258
2025
Q1 		$210K Sell
26,438
-154,916
-85% -$1.13M ﹤0.01% 5217
2024
Q4 		$985K Buy
181,354
+30,531
+20% +$187K ﹤0.01% 4646
2024
Q3 		$1.09M Sell
150,823
-1,049,152
-87% -$9.61M ﹤0.01% 4417
2024
Q2 		$13M Buy
1,199,975
+45,259
+4% +$580K ﹤0.01% 2219
2024
Q1 		$21.6M Sell
1,154,716
-515,999
-31% -$11.9M ﹤0.01% 1825
2023
Q4 		$36.2M Buy
1,670,715
+2,197
+0.1% +$43.5K ﹤0.01% 1410
2023
Q3 		$34.3M Sell
1,668,518
-24,076
-1% -$695K ﹤0.01% 1305
2023
Q2 		$79.6M Buy
1,692,594
+317,276
+23% +$15.8M 0.01% 931
2023
Q1 		$57.7M Sell
1,375,318
-37,513
-3% -$1.61M 0.01% 1032
2022
Q4 		$53.9M Sell
1,412,831
-115,916
-8% -$4.43M 0.01% 1073
2022
Q3 		$59.9M Sell
1,528,747
-22,720
-1% -$878K 0.01% 966
2022
Q2 		$50.1M Sell
1,551,467
-62,183
-4% -$2.08M 0.01% 1037
2022
Q1 		$53.4M Buy
1,613,650
+52,028
+3% +$1.96M 0.01% 1130
2021
Q4 		$66.4M Buy
1,561,622
+397,001
+34% +$16.6M 0.01% 1066
2021
Q3 		$51.6M Buy
1,164,621
+22,895
+2% +$1.05M 0.01% 1162
2021
Q2 		$64.9M Buy
1,141,726
+12,410
+1% +$877K 0.01% 1095
2021
Q1 		$84.5M Sell
1,129,316
-376,759
-25% -$30.9M 0.01% 925
2020
Q4 		$130M Sell
1,506,075
-30,001
-2% -$2.21M 0.02% 678
2020
Q3 		$91.7M Buy
1,536,076
+145,767
+10% +$7.39M 0.02% 726
2020
Q2 		$57.8M Sell
1,390,309
-18,053
-1% -$655K 0.01% 834
2020
Q1 		$40.4M Buy
1,408,362
+20,418
+1% +$1.18M 0.01% 892
2019
Q4 		$100M Buy
1,387,944
+465,571
+50% +$57.3M 0.02% 664
2019
Q3 		$129M Buy
922,373
+8,172
+0.9% +$1.37M 0.03% 578
2019
Q2 		$165M Sell
914,201
-37,867
-4% -$6.46M 0.03% 509
2019
Q1 		$151M Buy
952,068
+526
+0.1% +$76.2K 0.03% 516
2018
Q4 		$91.1M Buy
951,542
+15,484
+2% +$1.77M 0.02% 654
2018
Q3 		$132M Buy
936,058
+3,100
+0.3% +$478K 0.03% 586
2018
Q2 		$146M Buy
932,958
+211,272
+29% +$33.2M 0.03% 545
2018
Q1 		$116M Sell
721,686
-65,621
-8% -$11.1M 0.02% 577
2017
Q4 		$130M Sell
787,307
-50,787
-6% -$4.92M 0.03% 544
2017
Q3 		$52.7M Buy
838,094
+19,423
+2% +$1.53M 0.01% 898
2017
Q2 		$65.2M Sell
818,671
-15,624
-2% -$1.13M 0.01% 790
2017
Q1 		$59.3M Sell
834,295
-164,492
-16% -$9.64M 0.01% 856
2016
Q4 		$51M Sell
998,787
-207,757
-17% -$9.79M 0.01% 881
2016
Q3 		$55.6M Buy
1,206,544
+130,431
+12% +$5.31M 0.01% 779
2016
Q2 		$32.4M Buy
1,076,113
+50,123
+5% +$1.67M 0.01% 1066
2016
Q1 		$32.9M Buy
1,025,990
+59,582
+6% +$2.1M 0.01% 1032
2015
Q4 		$56.3M Buy
966,408
+66,948
+7% +$3.32M 0.01% 760
2015
Q3 		$38.1M Buy
899,460
+89,822
+11% +$5.54M 0.01% 916
2015
Q2 		$59.1M Buy
809,638
+14,846
+2% +$954K 0.01% 816
2015
Q1 		$39.9M Buy
794,792
+616,721
+346% +$26.5M 0.01% 997
2014
Q4 		$6.52M Buy
178,071
+119,296
+203% +$4.45M ﹤0.01% 2233
2014
Q3 		$1.85M Buy
+58,775
New +$1.7M ﹤0.01% 2972

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's SAGE Position: Q3 2025 in Review

JP Morgan Chase sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 132,912 shares — an estimated $1.21M sold.

JP Morgan Chase first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $165M in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • JP Morgan Chase reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 132,912 Sage Therapeutics shares in Q3 2025, an estimated $1.21M.
  • JP Morgan Chase first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • JP Morgan Chase's Sage Therapeutics position peaked at $165M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.